Taro-Carbamazepine: Formulary list price $0.1702/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1702 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68372 · Verify on the e-Formulary ↗ (DIN 02244403)
Source record
DIN 02244403: Taro-Carbamazepine
Raw flags: sec3=Y
Item: 281200049; group id 421; item number 1041; lccId None; manufacturer id TAR
Source form: Chew Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.1702; ministry $0.1702
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02244403
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68372Interchangeable products
Tegretol · DIN 00369810 · not recorded
Shortage status: resolved shortage (ended 2025-02-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244403
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Taro-Carbamazepine · DIN 02367394 · 100mg/5mL · Oral suspension
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Taro-Carbamazepine · DIN 02367394
Manufacturer: Taro Pharmaceuticals Inc.; listing date 2012-03-26
Health Canada: Marketed since 2011-10-07 · brand TARO-CARBAMAZEPINE · ATC N03AF01 CARBAMAZEPINE · form Suspension · route Oral · ingredients CARBAMAZEPINE 100 MG/5ML · company Taro pharmaceuticals inc · schedule Prescription
Taro-Carbamazepine: Formulary list price $0.0578/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0578 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85224 · Verify on the e-Formulary ↗ (DIN 02367394)
Source record
DIN 02367394: Taro-Carbamazepine
Raw flags: sec3=Y
Item: 281200067; group id 423; item number 1047; lccId None; manufacturer id TAR
Source form: Oral Susp; strength: 100mg/5mL
Recorded listing: General benefit
Source prices (unrounded): $0.0578; ministry $0.0578
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02367394
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85224Interchangeable products
Tegretol · DIN 02194333 · $0.0578
Shortage status: resolved shortage (ended 2026-08-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02367394
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Tegretol · DIN 02194333 · 100mg/5mL · Oral suspension
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Tegretol · DIN 02194333
Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-12-19
Health Canada: Marketed since 1999-06-10 · brand TEGRETOL SUSPENSION · ATC N03AF01 CARBAMAZEPINE · form Suspension · route Oral · ingredients CARBAMAZEPINE 100 MG/5ML · company Novartis pharmaceuticals canada inc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19729 · Verify on the e-Formulary ↗ (DIN 02194333)
Source record
DIN 02194333: Tegretol
Raw flags: sec3=Y
Item: 281200067; group id 423; item number 1047; lccId None; manufacturer id NOV
Source form: Oral Susp; strength: 100mg/5mL
Recorded listing: General benefit
Source prices (unrounded): $0.1182; ministry $0.0578
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02194333
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19729Interchangeable products
Taro-Carbamazepine · DIN 02367394 · $0.0578
Shortage status: resolved shortage (ended 2026-01-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02194333
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Taro-Carbamazepine · DIN 02244404 · 200mg · chewable tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Taro-Carbamazepine · DIN 02244404
Manufacturer: Taro Pharmaceuticals Inc.; listing date 2003-04-16
Health Canada: Marketed since 2002-04-19 · brand TARO-CARBAMAZEPINE CHEWABLE TABLETS · ATC N03AF01 CARBAMAZEPINE · form Tablet (chewable) · route Oral · ingredients CARBAMAZEPINE 200 MG · company Taro pharmaceuticals inc · schedule Prescription
Taro-Carbamazepine: Formulary list price $0.3302/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3302 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68373 · Verify on the e-Formulary ↗ (DIN 02244404)
Source record
DIN 02244404: Taro-Carbamazepine
Raw flags: sec3=Y
Item: 281200050; group id 421; item number 1042; lccId None; manufacturer id TAR
Source form: Chew Tab; strength: 200mg
Recorded listing: General benefit
Source prices (unrounded): $0.3302; ministry $0.3302
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02244404
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68373Interchangeable products
Tegretol · DIN 00665088 · not recorded
Shortage status: resolved shortage (ended 2020-03-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244404
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Carbamazepine CR · DIN 02261839 · 200mg · LA tablet
Limited Use — Reason for Use code 67 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 67 required
Write on scriptLU code 67 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 67
Reason for Use code 67
For patients who have been tried on conventional carbamazepine with unsatisfactory results due to adverse effects or poor control of symptoms.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Sandoz Carbamazepine CR · DIN 02261839
Manufacturer: Sandoz Canada Inc.; listing date 2006-07-19
Health Canada: Marketed since 2006-02-02 · brand SANDOZ-CARBAMAZEPINE CR · ATC N03AF01 CARBAMAZEPINE · form Tablet (extended-release) · route Oral · ingredients CARBAMAZEPINE 200 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Carbamazepine CR: Formulary list price $0.3845/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3845 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74720 · Verify on the e-Formulary ↗ (DIN 02261839)
Source record
DIN 02261839: Sandoz Carbamazepine CR
Raw flags: sec12=Y, sec3=Y
Item: 281200065; group id 422; item number 1045; lccId 00070; manufacturer id SDZ
Source form: LA Tab; strength: 200mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3845; ministry $0.3845
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02261839
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74720Interchangeable products
Tegretol CR · DIN 00773611 · $0.3845
Shortage status: shortage reported ended 2026-09-08 (report last updated 2026-09-08); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02261839
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Tegretol CR · DIN 00773611 · 200mg · LA tablet
Limited Use — Reason for Use code 67 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 67 required
Write on scriptLU code 67 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 67
Reason for Use code 67
For patients who have been tried on conventional carbamazepine with unsatisfactory results due to adverse effects or poor control of symptoms.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Tegretol CR · DIN 00773611
Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01
Health Canada: Marketed since 1999-03-10 · brand TEGRETOL CR · ATC N03AF01 CARBAMAZEPINE · form Tablet (extended-release) · route Oral · ingredients CARBAMAZEPINE 200 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8373 · Verify on the e-Formulary ↗ (DIN 00773611)
Source record
DIN 00773611: Tegretol CR
Raw flags: sec12=Y, sec3=Y
Item: 281200065; group id 422; item number 1045; lccId 00070; manufacturer id NOV
Source form: LA Tab; strength: 200mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6161; ministry $0.3845
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00773611
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8373Interchangeable products
Sandoz Carbamazepine CR · DIN 02261839 · $0.3845
Shortage status: resolved shortage (ended 2024-07-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00773611
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Carbamazepine · DIN 02541238 · 200mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mint-Carbamazepine · DIN 02541238
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2024-06-28
Health Canada: Marketed since 2024-04-19 · brand MINT-CARBAMAZEPINE · ATC N03AF01 CARBAMAZEPINE · form Tablet · route Oral · ingredients CARBAMAZEPINE 200 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Carbamazepine: Formulary list price $0.2217/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2217 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102988 · Verify on the e-Formulary ↗ (DIN 02541238)
Source record
DIN 02541238: Mint-Carbamazepine
Raw flags: sec3=Y
Item: 281200015; group id 423; item number 1048; lccId None; manufacturer id MIN
Source form: Tab; strength: 200mg
Recorded listing: General benefit
Source prices (unrounded): $0.2217; ministry $0.2217
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02541238
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102988Interchangeable products
Tegretol · DIN 00010405 · not recorded
Teva-Carbamazepine · DIN 00782718 · $0.2217
Shortage status: resolved shortage (ended 2024-10-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02541238
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Carbamazepine · DIN 00782718 · 200mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Carbamazepine · DIN 00782718
Manufacturer: Teva Canada Limited; listing date 1996-10-01
Health Canada: Marketed since 2010-11-26 · brand TEVA-CARBAMAZEPINE · ATC N03AF01 CARBAMAZEPINE · form Tablet · route Oral · ingredients CARBAMAZEPINE 200 MG · company Teva canada limited · schedule Prescription
Teva-Carbamazepine: Formulary list price $0.2217/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2217 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9242 · Verify on the e-Formulary ↗ (DIN 00782718)
Source record
DIN 00782718: Teva-Carbamazepine
Raw flags: sec3=Y
Item: 281200015; group id 423; item number 1048; lccId None; manufacturer id TEV
Source form: Tab; strength: 200mg
Recorded listing: General benefit
Source prices (unrounded): $0.2217; ministry $0.2217
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00782718
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9242Interchangeable products
Mint-Carbamazepine · DIN 02541238 · $0.2217
Tegretol · DIN 00010405 · not recorded
Shortage status: resolved shortage (ended 2026-06-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00782718
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Carbamazepine CR · DIN 02261847 · 400mg · LA tablet
Limited Use — Reason for Use code 67 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 67 required
Write on scriptLU code 67 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 67
Reason for Use code 67
For patients who have been tried on conventional carbamazepine with unsatisfactory results due to adverse effects or poor control of symptoms.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Sandoz Carbamazepine CR · DIN 02261847
Manufacturer: Sandoz Canada Inc.; listing date 2006-07-19
Health Canada: Marketed since 2006-02-02 · brand SANDOZ-CARBAMAZEPINE CR · ATC N03AF01 CARBAMAZEPINE · form Tablet (extended-release) · route Oral · ingredients CARBAMAZEPINE 400 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Carbamazepine CR: Formulary list price $0.7689/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.7689 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74721 · Verify on the e-Formulary ↗ (DIN 02261847)
Source record
DIN 02261847: Sandoz Carbamazepine CR
Raw flags: sec12=Y, sec3=Y
Item: 281200066; group id 422; item number 1046; lccId 00070; manufacturer id SDZ
Source form: LA Tab; strength: 400mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.7689; ministry $0.7689
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02261847
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74721Interchangeable products
Tegretol CR · DIN 00755583 · $0.7689
Shortage status: resolved shortage (ended 2024-07-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02261847
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Tegretol CR · DIN 00755583 · 400mg · LA tablet
Limited Use — Reason for Use code 67 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 67 required
Write on scriptLU code 67 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 67
Reason for Use code 67
For patients who have been tried on conventional carbamazepine with unsatisfactory results due to adverse effects or poor control of symptoms.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Tegretol CR · DIN 00755583
Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01
Health Canada: Marketed since 1998-08-18 · brand TEGRETOL CR · ATC N03AF01 CARBAMAZEPINE · form Tablet (extended-release) · route Oral · ingredients CARBAMAZEPINE 400 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8374 · Verify on the e-Formulary ↗ (DIN 00755583)
Source record
DIN 00755583: Tegretol CR
Raw flags: sec12=Y, sec3=Y
Item: 281200066; group id 422; item number 1046; lccId 00070; manufacturer id NOV
Source form: LA Tab; strength: 400mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.2324; ministry $0.7689
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00755583
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8374Interchangeable products
Sandoz Carbamazepine CR · DIN 02261847 · $0.7689
Shortage status: resolved shortage (ended 2024-07-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00755583
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Tegretol · DIN 00010405 · 200mg · tablet
Listed, not a benefitMarketed · checked 2026-09-02
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Tegretol · DIN 00010405
Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01
Health Canada: Marketed since 1997-12-15 · brand TEGRETOL · ATC N03AF01 CARBAMAZEPINE · form Tablet · route Oral · ingredients CARBAMAZEPINE 200 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Tegretol: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=777 · Verify on the e-Formulary ↗ (DIN 00010405)
Source record
DIN 00010405: Tegretol
Raw flags: notABenefit=Y, sec3=Y
Item: 281200015; group id 423; item number 1048; lccId None; manufacturer id NOV
Source form: Tab; strength: 200mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00010405
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=777Interchangeable products
Mint-Carbamazepine · DIN 02541238 · $0.2217
Teva-Carbamazepine · DIN 00782718 · $0.2217
Shortage status: resolved shortage (ended 2024-10-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00010405
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Temporary benefitOntario PIN; no Health Canada record under this code
StatusTemporary benefit
Write on scriptcheck temporary-benefit rules below
Patient paysPatient pays: program not supplied; amount cannot be determined.
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Carbamazepine ER Tablets, USP 200mg · DIN 09858341
Manufacturer: Septa Pharmaceuticals Inc.; listing date 2024-06-28
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
DIN 09858341: Carbamazepine ER Tablets, USP 200mg
Raw flags: sec3c=Y
Item: 281200186; group id 421; item number 1043; lccId None; manufacturer id SET
Source form: ER Tab; strength: 200mg
Recorded listing: Temporary benefit (shortage substitute)
Source prices (unrounded): $4.7080; ministry $4.7080
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09858341
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=09858341
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Temporary benefitOntario PIN; no Health Canada record under this code
StatusTemporary benefit
Write on scriptcheck temporary-benefit rules below
Patient paysPatient pays: program not supplied; amount cannot be determined.
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Carbamazepine ER Tablets, USP 400mg · DIN 09858342
Manufacturer: Septa Pharmaceuticals Inc.; listing date 2024-06-28
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
DIN 09858342: Carbamazepine ER Tablets, USP 400mg
Raw flags: sec3c=Y
Item: 281200187; group id 421; item number 1044; lccId None; manufacturer id SET
Source form: ER Tab; strength: 400mg
Recorded listing: Temporary benefit (shortage substitute)
Source prices (unrounded): $5.2216; ministry $5.2216
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09858342
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=09858342
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Tegretol · DIN 00369810 · 100mg · chewable tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-09-27 — choose a marketed DIN from the same-category list.Discontinued 2017-09-27 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-09-27 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-09-27 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Tegretol · DIN 00369810
Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2017-09-27 · brand TEGRETOL CHEWTABS 100 MG · ATC N03AF01 CARBAMAZEPINE · form Tablet (chewable) · route Oral · ingredients CARBAMAZEPINE 100 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Tegretol: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6049 · Verify on the e-Formulary ↗ (DIN 00369810)
Source record
DIN 00369810: Tegretol
Raw flags: notABenefit=Y, sec3=Y
Item: 281200049; group id 421; item number 1041; lccId None; manufacturer id NOV
Source form: Chew Tab; strength: 100mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00369810
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6049Interchangeable products
Taro-Carbamazepine · DIN 02244403 · $0.1702
Shortage status: discontinued (2017-08-18, reported by NOVARTIS PHARMACEUTICALS CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00369810
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2017-09-27 — choose a marketed DIN from the same-category list.
Tegretol · DIN 00665088 · 200mg · chewable tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-09-26 — choose a marketed DIN from the same-category list.Discontinued 2017-09-26 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-09-26 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-09-26 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Tegretol · DIN 00665088
Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2017-09-26 · brand TEGRETOL CHEWTABS 200 MG · ATC N03AF01 CARBAMAZEPINE · form Tablet (chewable) · route Oral · ingredients CARBAMAZEPINE 200 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Tegretol: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6463 · Verify on the e-Formulary ↗ (DIN 00665088)
Source record
DIN 00665088: Tegretol
Raw flags: notABenefit=Y, sec3=Y
Item: 281200050; group id 421; item number 1042; lccId None; manufacturer id NOV
Source form: Chew Tab; strength: 200mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00665088
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6463Interchangeable products
Taro-Carbamazepine · DIN 02244404 · $0.3302
Shortage status: discontinued (2017-06-05, reported by NOVARTIS PHARMACEUTICALS CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00665088
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2017-09-26 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered
Matched class: 28:12 Anticonvulsants
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: CLONAZEPAM, DIVALPROEX SODIUM, ETHOSUXIMIDE, LAMOTRIGINE, VALPROATE SODIUM
Some products covered without a code (check the product listing): GABAPENTIN, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PREGABALIN, PRIMIDONE, TOPIRAMATE, VALPROIC ACID
28:12 Anticonvulsants
· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab
· 5 products · General benefit · strengths: 50mg/mL · O/L
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:12
and 11 more
1. Indications
Epilepsy:
Adults (> 18 years of age)
TEGRETOL® (carbamazepine) is indicated for use as an anticonvulsant drug either alone or in
combination with other anticonvulsant drugs.
Carbamazepine is not effective in controlling absence, myoclonic or atonic seizures, and does not
prevent the generalization of epileptic discharge. Moreover, exacerbation of seizures may
occasionally occur in patients with atypical absences.
Trigeminal Neuralgia:
Adults (> 18 years of age)
TEGRETOL is indicated for the symptomatic relief of pain of trigeminal neuralgia only during periods of
exacerbation of true or primary trigeminal neuralgia (tic douloureux). It should not be used
preventively during periods of remission. In some patients, TEGRETOL has relieved glossopharyngeal
neuralgia. For patients who fail to respond to TEGRETOL, or who are sensitive to the drug, recourse to
other accepted measures must be considered.
Carbamazepine is not a simple analgesic and should not be used to relieve trivial facial pains or
headaches.
Treatment of Acute Mania and Prophylaxis in Bipolar (Manic-Depressive) Disorders:
Adults (> 18 years of age)
TEGRETOL may be used…
https://pdf.hres.ca/dpd_pm/00085662.PDF
PM date: 2026-07-31
Source product: TEGRETOL; DIN 00010405; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Sandoz Carbamazepine CR · DIN 02261839
Shortage status: shortage reported ended 2026-09-08 (report last updated 2026-09-08); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02261839
For Tegretol: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.